Overview
Esophagitis grade II, characterized by moderate inflammation of the esophageal mucosa, represents a significant clinical entity often secondary to gastroesophageal reflux disease (GERD) or other irritants. It manifests as symptoms ranging from dysphagia and heartburn to more severe discomfort, impacting quality of life notably among adults. Early recognition and management are crucial to prevent progression to more severe grades of esophagitis or complications such as strictures and Barrett's esophagus. Understanding and effectively managing grade II esophagitis is essential for clinicians to optimize patient outcomes and reduce morbidity in day-to-day practice 1.Pathophysiology
Esophagitis grade II typically arises from persistent exposure to gastric acid and other irritants that breach the protective barriers of the esophageal mucosa. At the cellular level, this exposure triggers a cascade of inflammatory responses, including the activation of mast cells and the release of pro-inflammatory cytokines such as TNF-α and IL-8 1. These inflammatory mediators contribute to mucosal edema, increased vascular permeability, and the recruitment of inflammatory cells like neutrophils and lymphocytes. Over time, this chronic inflammation can lead to architectural changes in the esophageal lining, including erosions and ulcerations, distinguishing grade II from milder forms by the presence of significant but superficial mucosal damage without deep necrosis 1.Epidemiology
The incidence of esophagitis varies widely depending on geographic location and population characteristics. In Western populations, GERD-related esophagitis affects approximately 10-20% of adults, with higher prevalence noted in older age groups and those with obesity or hiatal hernia 1. Gender differences are minimal, though some studies suggest a slight male predominance. Trends over time indicate an increasing prevalence, possibly linked to lifestyle factors such as dietary habits and obesity rates. Specific risk factors include smoking, alcohol consumption, and certain medications like NSAIDs, which can exacerbate esophageal irritation and inflammation 1.Clinical Presentation
Patients with esophagitis grade II commonly present with symptoms such as heartburn, regurgitation, dysphagia, and epigastric pain, often exacerbated by lying down or eating. Atypical presentations might include chronic cough, hoarseness, or chest pain mimicking cardiac issues. Red-flag features include significant weight loss, persistent odynophagia (painful swallowing), and hematemesis, which warrant urgent evaluation for complications such as bleeding or strictures 1. Accurate clinical history and symptomatology are crucial for guiding further diagnostic workup.Diagnosis
The diagnosis of esophagitis grade II typically involves a combination of clinical assessment and endoscopic evaluation. Endoscopy remains the gold standard, allowing direct visualization of mucosal changes and grading based on the Los Angeles Classification System, where grade II corresponds to multifocal (≥2) but no stricture-forming lesions 1. Specific diagnostic criteria include:Management
First-Line Treatment
Second-Line Treatment
Specialist Escalation
Complications
Common complications of untreated or poorly managed grade II esophagitis include:Prognosis & Follow-up
The prognosis for grade II esophagitis is generally favorable with appropriate management, often leading to symptom resolution and mucosal healing within weeks to months. Prognostic indicators include adherence to treatment, resolution of underlying GERD, and absence of significant comorbidities. Recommended follow-up intervals typically involve:Special Populations
Pediatrics
In children, esophagitis grade II is less common but can occur due to GERD exacerbated by feeding practices or anatomical anomalies. Management focuses on PPI therapy at lower doses (e.g., Lansoprazole 1 mg/kg daily) and lifestyle adjustments tailored to pediatric needs 1.Elderly
Elderly patients may present with atypical symptoms and have higher rates of comorbidities affecting treatment choices. PPI dosing might need adjustment based on renal function, and close monitoring for drug interactions is essential 1.Comorbidities
Patients with comorbidities like obesity, hiatal hernia, or connective tissue disorders (e.g., scleroderma) require tailored approaches, often necessitating higher vigilance and possibly more aggressive initial treatment strategies 1.Key Recommendations
References
1 Barefoot JC, Dodge KA, Peterson BL, Dahlstrom WG, Williams RB. The Cook-Medley hostility scale: item content and ability to predict survival. Psychosomatic medicine 1989. link